Mavoglurant Sales Forecast Summary

Key Factors Driving Mavoglurant Growth

Strong Scientific Rationale: mGluR5 Pathway Modulation

• Mavoglurant is a selective mGluR5 (metabotropic glutamate receptor 5) antagonist
• Mechanism:
  • Reduces excessive glutamate signaling
  • Modulates synaptic plasticity and reward pathways 
• Relevance:
  • mGluR5 plays a critical role in:
    • Addiction reward circuits
    • Drug-seeking behavior
• Preclinical studies show:
  • Reduced cocaine self-administration
  • Restoration of neural abnormalities 

Clinical Proof-of-Concept in Cocaine Use Disorder (Major Growth Driver)

Phase II Clinical Trial (2025)

• Randomized, placebo-controlled study (n=68):
  • Significant reduction in cocaine use vs placeb
• Treatment duration:
  • ~98 days with oral dosing
• Additional findings:
  • Reduction in alcohol use trends (non-significant) 

First-Mover Opportunity in Cocaine Use Disorder

• NFDA-approved pharmacotherapies for cocaine use disorder (CUD)
• Current standard:
  • Behavioral therapy only
• Implication:
  • If approved, mavoglurant could:
    • Be first-in-class pharmacologic therapy
    • Capture significant early market share

Favorable Safety and Tolerability Profile

• Across multiple trials:
  • Well tolerated with nmajor safety signals 
• Long-term exposure:
  • Up t34 months in extension studies with acceptable safety 

Oral Administration & Scalable Treatment Model

• Oral, twice-daily dosing used in trials 
• Advantages:
  • Easy integration intaddiction clinics
  • Nneed for supervised administration (vs some competitors)

Multi-Indication Expansion Potential

Beyond cocaine use disorder, mGluR5 modulation is relevant in:

• Alcohol use disorder (signals observed in trials) 
• Nicotine dependence (preclinical rationale)
• Other neuropsychiatric disorders 

Mavoglurant Recent Developments

STALICLA announced it concluded a Phase III enabling drug-drug interaction study for mavoglurant (now referred tas STP7) in October 2024. The Phase III development of mavoglurant for CUD is fully financed and supported by the NIH-National Institute on Drug Abuse (NIDA) via a Collaborative Research and Development Agreement (CRADA).  

“Mavoglurant Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Mavoglurant for potential indication like Alcoholism and Cocaine-related disorders in the 7MM. A detailed picture of Mavoglurant’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Mavoglurant for potential indications. The Mavoglurant market report provides insights about Mavoglurant’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it alsconsists of historical and current Mavoglurant performance, future market assessments inclusive of the Mavoglurant market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It alsprovides analysis of Mavoglurant sales forecasts, along with factors driving its market.

Mavoglurant Drug Summary

Mavoglurant (AFQ056) is an investigational, selective negative allosteric modulator (NAM) of the metabotropic glutamate receptor 5 (mGluR5), developed primarily by Novartis, that binds tan allosteric site tinhibit glutamate signaling, thereby modulating synaptic plasticity, neural network activity, and downstream effectors like phosphatidylinositol-calcium pathways without directly competing at the orthosteric site. Initially pursued for fragile X syndrome (FXS), where Phase II trials showed behavioral improvements in fully methylated FMR1 patients but failed tmeet primary endpoints in larger studies, and L-DOPA-induced dyskinesia in Parkinson's disease, it has been explored in other indications including OCD, Huntington's chorea (discontinued due tlack of efficacy), and more recently cocaine use disorder (CUD). The report provides Mavoglurant’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Mavoglurant Market Report 

The report provides insights into:

• A comprehensive product overview including the Mavoglurant MoA, description, dosage and administration, research and development activities in potential indication like Alcoholism and Cocaine-related disorders.
• Elaborated details on Mavoglurant regulatory milestones and other development activities have been provided in Mavoglurant market report.
• The report alshighlights Mavoglurant‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan. 
• The Mavoglurant market report alscovers the patents information, generic entry and impact on cost cut.
• The Mavoglurant market report contains current and forecasted Mavoglurant sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Mavoglurant market report alsfeatures the SWOT analysis with analyst views for Mavoglurant in potential indications.

Methodology

The Mavoglurant market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access tavailable databases.

Mavoglurant Analytical Perspective by DelveInsight

• In-depth Mavoglurant Market Assessment

This Mavoglurant sales market forecast report provides a detailed market assessment of Mavoglurant for potential indication like Alcoholism and Cocaine-related disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Mavoglurant sales data uptil 2034.

• Mavoglurant Clinical Assessment

The Mavoglurant market report provides the clinical trials information of Mavoglurant for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Mavoglurant Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Mavoglurant Market Potential & Revenue Forecast

• Projected market size for the Mavoglurant and its key indications
• Estimated Mavoglurant sales potential (Mavoglurant peak sales forecasts)
• Mavoglurant Pricing strategies and reimbursement landscape

Mavoglurant Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Mavoglurant Market positioning compared texisting treatments
• Mavoglurant Strengths & weaknesses relative tcompetitors

Mavoglurant Regulatory & Commercial Milestones

• Mavoglurant Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Mavoglurant Clinical Differentiation

• Mavoglurant Efficacy & safety advantages over existing drugs
• Mavoglurant Unique selling points 

Mavoglurant Market Report Highlights 

• In the coming years, the Mavoglurant market scenariis set tchange due tstrong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Mavoglurant companies are developing therapies that focus on novel approaches ttreat/improve the disease condition, assess challenges, and seek opportunities that could influence Mavoglurant’s dominance.
• Other emerging products for Alcoholism and Cocaine-related disorders are expected tgive tough market competition tMavoglurant and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenariof Mavoglurant in potential indications.
• Analyse Mavoglurant cost, pricing trends and market positioning tsupport strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Mavoglurant sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfoliby identifying the overall scenariof Mavoglurant in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Mavoglurant? How strong is Mavoglurant’s clinical and commercial performance?
• What is Mavoglurant’s clinical trial status in each individual indications such as Alcoholism and Cocaine-related disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related tthe Mavoglurant Manufacturers?
• What are the key designations that have been granted tMavoglurant for potential indications? How are they going timpact Mavoglurant’s penetration in various geographies?
• What is the current and forecasted Mavoglurant market scenarifor potential indications? What are the key assumptions behind the forecast? 
• What are the current and forecasted sales of Mavoglurant in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition tMavoglurant for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Mavoglurant? What is the duration of therapy and what are the geographical variations in cost per patient?